psi-697
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2006 (NCT00367692)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- P-selectinINHIBITOR
SELP inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)c1c(O)c(Cc2ccc(Cl)cc2)nc2c3c(ccc12)CCCC3- Mol. weight
- 367.83 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL219046 ↗
Also known as
- 2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo(h)quinoline-4-carboxylic acid
- psi697
- psi 697
- psi-697
- psi-697
- psi-697
- psi-697
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00719069 | Phase 1 | Apr 1, 2008 | Pfizer, Wyeth |
| NCT03860506 | Phase 1 | Apr 1, 2008 | Pfizer |
| NCT00367692 | Phase 1 | Sep 1, 2006 | Pfizer, Wyeth |
Showing 3 of 3 trials
Page 1 / 1